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Abstract
Introduction Accurate determination of human epidermal
growth factor receptor 2 (HER2) status is essential for optimal
patient management with trastuzumab (Herceptin). However,
standard guidelines do not specify a particular commercial kit,
antibody or probe for testing, and discrepancies arise from
variability between kits. The aim of this study was to compare the
accuracy of four commercially available fluorescence/
chromogenic in situ hybridisation (FISH/CISH) kits and validate
one for the resolution of borderline immunohistochemistry (IHC)
cases. The interpretation pitfalls, optimal threshold values, assay
duration and complexity of each kit were also considered.
Methods The Food and Drug Administration (FDA)-approved
dual-probe FISH assay PathVysion was chosen as the 'gold
standard' against which pharmDx (dual-probe) and INFORM
(mono-probe) FDA-approved FISH kits and the SPoT-Light
CISH kit were compared. Tumours were also evaluated by IHC
with the FDA-approved HercepTest kit and a validated in-house
IHC protocol. Fifty-five patients with invasive breast carcinoma
were selected as a representative proportion of HER2 IHC 2+
cases.
Results HER2 amplification was observed in 31% of tumours
by PathVysion compared with 33% with pharmDx. The number
of amplified tumours detected by INFORM and CISH varied with
the threshold applied. Agreement was excellent between
PathVysion and pharmDx (100%), good with SPoT-Light (89%;
cutoff at least five signals per nucleus) and moderate with
INFORM (76%; cutoff more than four signals per nucleus).
Agreement with INFORM improved to 98% with a cutoff of at
least six signals per nucleus.
Conclusion With an appropriate cutoff, the INFORM kit was
comparable to dual-probe FISH kits for evaluating HER2 status.
We validate and recommend CISH as an appropriate assay for
HER2 scoring that is easy to interpret and requires equipment
readily found in, or that can be adapted to, all pathology
laboratories. For borderline IHC cases, dual-probe FISH
analysis remains the most useful protocol to apply.
Introduction
About 20 to 30% of breast cancer tumours are positive for
amplification and overexpression of human epidermal growth
factor receptor 2 (HER2), which is associated with poor prog-
nosis and clinical outcome [1-3]. HER2 is targeted therapeu-
tically by the humanised monoclonal antibody trastuzumab
(Herceptin; F Hoffman-La Roche Ltd, Basel, Switzerland).
Trastuzumab is effective only in patients whose tumours are
positive for HER2 gene amplification and/or protein overex-
pression [4-7]. Therefore, accurate HER2 testing is essential
for selecting patients eligible for trastuzumab-based therapies.
Originally, HER2 status was determined by Southern blotting
[3,8], but the present methods of evaluation combine immuno-
histochemistry (IHC) and fluorescence/chromogenic in situ
hybridisation (FISH/CISH). Inconsistencies arise in HER2
scoring because of the variety of commercial assays available,
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which use different antibodies and probes. Although the Col-
lege of American Pathologists [9] and a UK-based study [10]
recommend IHC and FISH for HER2 testing, neither specify a
particular commercial kit.
In the present study, the Food and Drug Administration (FDA)-
approved dual-probe FISH assay PathVysion (Abbott France
SAS, Rungis, France) was used as 'gold standard' against
which the FDA-approved dual-probe pharmDx (Dako France
SAS, Trappes, France) and mono-probe INFORM (Ventana
Medical Systems SA, Illkirch, France) FISH assays, plus the
CISH assay SPoT-Light (Zymed Laboratories Inc., San Fran-
cisco, CA, USA) were compared. Invasive tumour specimens
from 55 patients were evaluated for HER2 status with these
different methods. This study is the first, to our knowledge, that
compares three commercially available FISH analysis kits with
CISH, and evaluates the respective thresholds of each assay.
Materials and methods
Samples
Tumour samples from 55 patients with invasive breast carci-
noma were collected for evaluation between January 2001
and April 2003. All samples were fixed in neutral-buffered for-
malin and embedded in paraffin. Cases were selected to
ensure a representative proportion of HER2 IHC 2+ cases,
and blind assessments were made of the invasive tumour com-
ponent of all samples by two independent pathologists.
The study was conducted in line with the Declaration of Hel-
sinki and Good Clinical Practice, and with the approval of an
independent Institutional Review Board.
Immunohistochemistry
Tumour samples were assessed for HER2 status with the
FDA-approved HercepTest kit (Dako) and a standardised in-
house laboratory technique with the rabbit anti-human HER2
polyclonal A0485 (1:400 dilution; Dako) for 32 minutes [11].
Tissue sections (3 μm) were deparaffinised and rehydrated,
and antigens were retrieved for 40 minutes in citrate buffer
(pH 6.1) at 95°C. IHC was performed with the NexES auto-
mated immunostaining system and diaminobenzidine detec-
tion kit (Ventana Medical Systems SA). Staining intensity was
graded in accordance with the HercepTest protocol system as
0, 1+, 2+ or 3+. Samples scored as 0 or 1+ were considered
negative for HER2 overexpression, 2+ was weak positive and
3+ was strong positive, with complete membrane staining of
more than 10% of tumour cells.
Fluorescence in situ hybridisation
The FDA-approved PathVysion and pharmDx assays were
used in accordance with the manufacturers' recommended
protocols but with some minor modifications. The DNA
probes, HER2-specific sequence probe (LSI HER2/neu),
chromosome enumeration probe 17 (CEP17) and tissue sec-
tions were denatured for 5 minutes at 85°C (PathVysion) or
82°C (pharmDx) with a HYBrite instrument (Abbott France
SAS). An additional wash in distilled water was performed
before counterstaining and mounting with a solution of 4,6-
diamidino-2-phenylindole (DAPI). As the intensity of fluores-
cence observed with the DAPI solution provided in the
pharmDx kit was poor, the commercially available VECTASH-
IELD plus DAPI mounting medium (AbCys SA, Paris, France)
was used instead for these samples. The results are reported
as the ratio of average HER2:CEP17 signals per nucleus. Sig-
nal ratios of less than two were classified as non-amplified
(NA), and ratios of two or more as amplified.
The INFORM assay, an automated system using the Bench-
Mark automated staining system (Ventana Medical Systems
SA), was used in accordance with the manufacturer's recom-
mended protocols. Amplification was defined as more than
four signals per nucleus, as stated in the manufacturer's guide-
lines. Additional thresholds were applied (more than five and
at least six signals per nucleus) for comparison and optimisa-
tion. At least 30 nuclei were counted for signals in each
section.
Chromogenic in situ hybridisation
CISH analysis of HER2 amplification was performed with the
SPoT-Light assay in accordance with the manufacturer's pro-
tocol. The DNA probe (HER2 SPoT-Light) and sections were
denatured at 94 to 95°C and hybridised overnight at 37°C
with a HYBrite instrument. Amplification was defined with two
thresholds – more than five or at least six signals per nucleus
– detected in more than 50% of nuclei or when a large signal
cluster was detected. At least 30 nuclei were counted per
section.
Statistics
PathVysion was used as the 'gold standard' against which all
protocols were compared, and agreement was quantified with
pairwise kappa (κ) statistics. The analytical performance of
these kits was also estimated for specificity and sensitivity.
The pairwise χ2 test was used to assess overvaluation or
undervaluation of HER2 status.
Results
HER2 status for all samples as determined by IHC, FISH and
CISH are detailed in Table 1.
Immunohistochemistry
With the A0485 antibody-based in-house IHC protocol, 18
tumours (33%) were scored as IHC 3+, 17 (31%) as IHC 2+
and 20 (36%) as IHC 0/1+ (HER2 negative). In contrast, Her-
cepTest identified 25 tumours (45%) as IHC 3+ and 12
(22%) as 2+ (HER2-positive); 18 (33%) were scored as IHC
0/1+ (HER2-negative). The κ coefficient between the two
tests was 0.427 ± 0.083 (SD) and agreement was 58% if in-
house IHC was considered as the reference standard. Con-
cordance between the two protocols was 70% for HER2-neg-Available online http://breast-cancer-research.com/content/9/5/R64
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Table 1
Evaluation of HER2 status by IHC, FISH and CISH
Case ID PathVysion pharmDx INFORM CISH In-house HercepTest
>4 >5 ≥6> 5≥6
1AAAAAAA33
2AAAAAAA33
3AAAAAAA33
4AAAAAAA33
5AAAAAAA33
6AAAAAAA33
7AAAAAAA33
8AAAAAAA33
9AAAAAAA33
1 0 AAAAAAA33
1 1 AAAAAAA33
1 2 AAAAAAA33
1 3 AAAAAAA33
1 4 AAAAAAA33
1 5 AAAAAAA33
1 6 AAAAAAA33
1 7 AAAAAAA23
18 NA NA NA NA NA NA NA 2 3
19 NA NA NA NA NA NA NA 2 2
2 0 N A N A AN A N A AA33
21 NA NA A A NA A NA 3 3
22 - A NA NA NA NA NA 2 3
2 3- N AN AN AN AN AN A2 1
2 4 N A N A AN A N A AA13
2 5 N A N A AAAAN A 23
26 NA NA A A NA A A 2 2
2 7N AN AA N AN AN AN A2 2
28 NA NA A A NA NA NA 2 2
2 9N AN AA N AN AN AN A2 1
30 NA NA A A NA NA NA 1 2
31 NA NA NA NA NA NA NA 1 1
3 2N AN AA N AN AN AN A0 0
33 NA NA A NA NA A NA 0 1
3 4N AN AA N AN AN AN A0 2
3 5N AN AA N AN AN AN A0 0
36 NA NA NA NA NA NA NA 0 1
37 NA NA NA NA NA NA NA 0 1Breast Cancer Research    Vol 9 No 5    Cayre et al.
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ative IHC 0/1+ cases, 47% for IHC 2+ and 100% for HER2-
positive IHC 3+ cases, if in-house IHC was considered as the
reference standard. All IHC 3+ cases demonstrated complete
membrane staining in at least 30% of tumour cells.
Fluorescence in situ hybridisation
Two cases could not be evaluated with the PathVysion kit but
were assessed and graded successfully using pharmDx and
INFORM. PathVysion identified 17 tumours (31%) as ampli-
fied, in comparison with 18 (33%) by pharmDx. INFORM had
three thresholds applied to determine the optimal cutoff for
evaluating positive HER2 amplification. These thresholds were
more than four signals per nucleus as recommended by the
manufacturer, more than five signals per nucleus as recom-
mended for CISH analysis, and at least six signals per nucleus
as recommended by Zymed for the SPoT-Light CISH kit used
in this study. Using a cutoff of more than four signals per
nucleus, 30 tumours (55%) were designated as amplified.
This was decreased to 22 (40%) when the threshold was
increased to more than five signals per nucleus. Application of
the threshold of at least six signals per nucleus decreased the
proportion of amplified samples to 18 (33%).
Chromogenic in situ hybridisation
Two different thresholds of more than five or at least six signals
per nucleus were used to establish the optimal cutoff point for
HER2 amplification by CISH. When the cutoff of more than
five signals per nucleus was applied, 23 tumours (42%) were
defined as amplified, and 32 (58%) as NA. In contrast, appli-
cation of the threshold of at least six signals per nucleus
decreased the number of amplified tumours to 20 (36%) and
increased the number of NA tumours to 35 (64%).
Inter-assay agreement
The PathVysion assay kit was chosen as the 'gold standard' for
comparisons. Agreement with PathVysion and other tech-
niques used to determine HER2 status is shown in Table 2.
There was excellent agreement (100%) between the dual-
probe techniques, namely PathVysion and pharmDx. However,
agreement between PathVysion and INFORM differed
depending on the threshold applied. The lowest level of agree-
ment between the two protocols (76%) occurred with a cutoff
of more than four signals per nucleus. This increased to 91%
with the threshold of more than five signals per nucleus, and to
98% with a cutoff of at least six signals per nucleus (Table 2).
Similarly, application of different thresholds to CISH altered
agreement with PathVysion. An agreement of 89% with a cut-
off of more than five signals per nucleus was increased to 94%
by changing the cutoff value to at least six signals per nucleus
(Table 2).
38 NA NA NA NA NA NA NA 2 3
39 NA NA NA NA NA NA NA 2 3
40 NA NA NA NA NA NA NA 2 2
41 NA NA NA NA NA NA NA 2 2
42 NA NA NA NA NA NA NA 2 2
43 NA NA NA NA NA NA NA 2 1
44 NA NA NA NA NA NA NA 2 0
45 NA NA NA NA NA NA NA 0 2
46 NA NA NA NA NA NA NA 0 2
47 NA NA NA NA NA NA NA 0 2
48 NA NA NA NA NA NA NA 0 1
49 NA NA NA NA NA NA NA 0 1
50 NA NA NA NA NA NA NA 0 1
51 NA NA NA NA NA NA NA 0 0
52 NA NA NA NA NA NA NA 0 0
53 NA NA NA NA NA NA NA 0 0
54 NA NA NA NA NA NA NA 0 0
55 NA NA NA NA NA NA NA 0 0
HER2, human epidermal growth factor receptor 2; A, amplified; NA, non-amplified; IHC, immunohistochemistry; FISH, fluorescence in situ 
hybridisation; CISH, chromogenic in situ hybridisation.
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For IHC, general agreement varied for the HercepTest and in-
house IHC protocol depending on whether IHC 2+ samples
were classified as positive (grouped with IHC 3+ cases) or
negative (grouped with IHC 0/1+ cases) (Table 2). When con-
sidering only HER2-negative IHC 0/1+ tumours, both proto-
cols demonstrated 100% concordance with PathVysion (data
not shown). Good agreement (89%) was demonstrated
between the in-house IHC protocol and PathVysion for the
evaluation of IHC 3+ tumours but HercepTest demonstrated
poor concordance at 68% (data not shown).
Details of the unmatched in situ hybridisation cases
There were 14 cases that scored differently for HER2 amplifi-
cation when using the various kits (Table 1). One case scored
as amplified with pharmDx but NA with the INFORM and
SPoT-Light assays when using all thresholds. The
HER2:CEP17 ratio of 2.27 highlighted low amplification but
this could not be confirmed with the alternative dual-probe kit
(PathVysion) (Table 3). Six cases were scored as amplified
(five with low amplification and one with presence of clusters)
with the use of the CISH SPoT-Light assay (threshold more
than five signals per nucleus) and NA with PathVysion. Four of
these tumours had chromosome 17 polysomy, with a mean
number of three signals per nucleus for CEP17 with PathVys-
ion. The mean number of CISH HER2 signals per nucleus for
the remaining two discrepant cases was 5.6 and clusters.
When CISH was used in conjunction with the threshold of at
least six signals per nucleus, only one case remained discrep-
ant with the presence of clusters (Table 3).
With the INFORM kit and a threshold of more than four signals
per nucleus, comparisons with the 'gold standard' PathVysion
identified an overvaluation of HER2 amplification in 13 speci-
mens (amplified with INFORM and NA with PathVysion). Over-
valuation was not random (P = 0.00031, paired-series χ2 test).
No false negatives were observed. Chromosome 17 polysomy
accounted for six of the unmatched cases considering PathVy-
sion and eight considering PathVysion and pharmDx, but the
remaining false positives could not be explained. Application
of the following thresholds reduced the number of false posi-
tives and improved agreement with PathVysion: more than five
signals per nucleus reduced the number of mismatches to five
with only one case that could not be explained by a polysomy,
and at least six signals per nucleus left only one unmatched
case, which could be explained by chromosome 17 polysomy
(Table 3). The cutoff points of more than five and at least six
signals per nucleus improved agreement from 76% to 91%
and 98%, respectively.
Technical and economic considerations
The minimum time requirements and direct costs for the differ-
ent techniques are presented in Table 4. CISH was the most
time-consuming method because it required immunodetection
of the amplification product after hybridisation; however,
excluding the in-house kit, it was the cheapest. INFORM was
less time-consuming because the staining protocol was
automated; PathVysion was the most expensive.
Comparisons of the different in situ hybridisation protocols are
listed in Table 5. CISH provides several technical advantages
over the FISH protocols assessed in this study. First, as CISH
uses a chromogenic peroxidase reaction to reveal amplifica-
tion signals, samples can be assessed with a standard light
microscope, allowing simultaneous viewing of staining and
histopathology. Second, because the chromogenic labels are
stable, samples can be stored easily at ambient temperature
for long periods without signal degeneration. However, there
are important disadvantages, namely the time associated with
Table 2
Concordance between PathVysion and other HER2-testing protocols
Comparison with PathVysion κ coefficient* Degree of agreement Agreement
(percentage)
Sensitivity
(percentage)
Specificity
(percentage)
PharmDx 1.000 Excellent 100 100 100
INFORM (at least six signals per nucleus) 0.916 ± 0.058 Excellent 98 100 94
INFORM (at least five signals per nucleus) 0.799 ± 0.085 Good 91 100 88
INFORM (more than four signals per nucleus) 0.532 ± 0.111 Moderate 76 100 57
CISH (at least six signals per nucleus) 0.876 ± 0.070 Excellent 94 100 94
CISH (at least five signals per nucleus) 0.762 ± 0.091 Good 89 100 88
In-house IHC (positive 3+, negative 0, 1+, 2+) 0.792 ± 0.089 Good 91 89 91
In-house IHC (positive 3+, 2+, negative 0, 1+) 0.475 ± 0.111 Moderate 72 100 57
HercepTest (positive 3+, negative 0, 1+, 2+) 0.645 ± 0.104 Good 83 89 80
HercepTest (positive 3+, 2+, negative 0, 1+) 0.350 ± 0.119 Poor 64 94 49
HER2, human epidermal growth factor receptor 2; CISH, chromogenic in situ hybridisation; IHC, immunohistochemistry. (* errors given as ± SD)Breast Cancer Research    Vol 9 No 5    Cayre et al.
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immunodetection of the amplification product and the lack of
dual chromogenic probes HER2:CEP17, although SPoT-Light
chromosome 17 is available.
Because FISH techniques use fluorophores to localise target
DNA, definition of cell morphology is poor; the best is
achieved with PathVysion. The key technical disadvantages
associated with PathVysion are that the solutions are not ready
to use, the reagent pH requires confirmation before use, and
fluorescent HER2 probes labelled with Spectrum Orange are
hard to detect above the high background fluorescence.
In contrast to the HER2 probe, the pharmDx CEP17 probe
was conjugated with fluorescein isothiocyanate (FITC), and
positive signals were transient and faint. The high background
fluorescence associated with this kit created problems when
evaluating the faint CEP17 signals.
The most significant technical disadvantage with INFORM is
the lack of dual fluorescence probes HER2:CEP17, which
would counter the level of false positives achieved with this kit
at its recommended threshold.
Discussion
Trastuzumab has a proven survival benefit in the treatment of
women with HER2-positive breast cancer. Accurate identifica-
tion of HER2 status is essential for identifying patients who
may benefit from HER2-targeted therapy. The protocols cur-
rently validated for use in routine diagnosis are IHC for identi-
fying HER2 protein overexpression, and FISH or CISH for
determining HER2 gene amplification. IHC and FISH are the
protocols of choice in the routine diagnosis of HER2 status,
providing reliable results. These protocols are reliable only if
they are validated within individual laboratories. It is essential
that protocols are adhered to, that quality-control and assur-
ance programmes are implemented, and that diagnostic per-
sonnel have experience and regular training in score
interpretation.
The UK best practice recommends a two-phase testing algo-
rithm based on first-line IHC evaluation and second-line FISH
assessment of borderline cases (IHC 2+) [10]. This correlates
with recommendations from the College of American Patholo-
gists if the concordance rates are more than 90% between
IHC 3+ and FISH amplified, IHC 0 and FISH NA, and 95%
between IHC 1+ and FISH NA. The in-house IHC was in
accordance with the criteria above; the algorithm was there-
fore applied to all samples. Our in-house IHC technique has
been calibrated with FISH within the framework of the Groupe
d'Étude des Facteurs Pronostiques par Immunohistochimie
dans le Cancer du Sein (GEFPICS) study [11]. This is not true
for HercepTest, for which the agreement was weaker (68%)
between IHC 3+ and PathVysion. However, HercepTest has
been proposed as the standard IHC method for HER2 status
Table 3
Details of the unmatched in situ hybridisation cases
Case ID PathVysion PharmDx™ INFORM CISH
HER2 signals 
per nucleus
CEP17 
signals per 
nucleus
Ratio HER2 signals 
per nucleus
CEP17 
signals per 
nucleus
Ratio HER2 signals 
per nucleus
HER2 signals 
per nucleus
20 5.6 5.3 (P) 1.1 6.2 4.0 (P) 1.6 4.9 6.4
21 2.2 2.5 0.9 5.1 3.3 (P) 1.6 5.6 5.6
2 2 ---4 . 5 2 . 0 2 . 3 3 . 8 3 . 6
2 4 2 . 62 . 51 . 03 . 32 . 61 . 24 . 3C l u s t e r s
25 3.7 3.8 (P) 1.0 6.2 4.0 (P) 1.6 7.7 5.5
26 4.4 2.8 1.6 6.1 4.2 (P) 1.5 5.3 6.6
2 7 3 . 42 . 21 . 53 . 82 . 41 . 64 . 83 . 7
28 3.8 3.7 (P) 1.0 4.0 3.4 (P) 1.2 5.7 4.9
2 9 2 . 02 . 01 . 03 . 52 . 01 . 74 . 43 . 6
30 4.6 3.3 (P) 1.4 5.7 3.7 (P) 1.5 5.5 3.4
3 2 2 . 02 . 50 . 82 . 02 . 01 . 04 . 24 . 9
33 5.6 5.0 (P) 1.1 5.2 3.5 (P) 1.5 4.5 5.7
3 4 3 . 32 . 21 . 53 . 32 . 11 . 64 . 12 . 5
3 5 3 . 13 . 5  ( P ) 0 . 92 . 82 . 71 . 04 . 23 . 3
HER2, human epidermal growth factor receptor 2; CEP17, chromosome enumeration probe 17; P, polysomy; CISH, chromogenic in situ 
hybridisation.Available online http://breast-cancer-research.com/content/9/5/R64
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evaluation, capable of overcoming the problems of standardi-
sation and reproducibility between laboratories. In agreement
with our results, several studies have demonstrated the exces-
sive sensitivity of this kit [12-14].
The goal of this study was to evaluate the accuracy of four
commercial  in situ hybridisation kits (three FISH and one
CISH) and validate a protocol for resolving borderline IHC
cases. The PathVysion kit was chosen as the 'gold standard'
because it has a proven record of sensitivity and specificity for
HER2 gene amplification against solid matrix blotting tech-
niques [8].
Concordance between this kit and pharmDx was 100% (the
manufacturers report a concordance of 95%); the perform-
ance of both kits can therefore be regarded as equivalent. Dif-
ferences arise in price, time and interpretation. PharmDx is
cheaper and faster than PathVysion but interpretation is more
difficult (except for highly amplified cases) because of strong
background fluorescence and the transient nature of the FITC
signal.
Agreement between PathVysion and CISH varied depending
on the threshold applied. Excellent agreement (94%) was
achieved with a cutoff of at least six signals per nucleus. All
patients with amplification of the HER2 gene were detected
(sensitivity of 100%); however, three false positives (specifi-
city of 94%) were reported with CISH. Two of these were low-
level amplifications, having chromosome 17 polysomy and
requiring confirmation of diagnosis with one of the dual-probe
FISH kits. This threshold recommended by Zymed for the
SPoT-Light CISH kit accounted for the occurrence of aneu-
ploid cell populations that can give three to five signals per
nucleus, and the manufacturer advised that these be inter-
preted as NA. In addition, a small proportion of aneuploid cells
may contain five to eight signals per nucleus because of DNA
replication during the S and G2/M phases of the cell cycle and
should also be regarded as NA.
Agreement between CISH and FISH in the literature varies
between 84% and 100% [15-19]. One study reported 100%
agreement between CISH and FISH when samples scoring
more than two signals per nucleus with HER2 CISH were sys-
tematically controlled for by using a chromosome 17 CISH
probe on adjacent sections [19]. CISH provides a good alter-
native to FISH in laboratories that lack access to fluorescence
microscopy. However, we recommend that for borderline
cases with CISH scores of more than five to ten signals per
Table 4
Summary of protocols and costs
Technical stage Stage presence or duration
PathVysion PharmDx INFORM CISH In-house
Deparaffinisation and 
rehydration
40 min 33 min Overnight in the
BenchMark
25 min 20 min
Pretreatment 67 min 31 min 21 min 60 min
Digestion 26 min 16 min 16 min No
Fixation 20 min No No Fixation, blocking, incubation with primary and 
secondary antibodies and detection, all performed in 
NexES 90 min
Dehydration No 6 min 10 min
Drying Yes Yes Yes
Denaturation 5 min 5 min 5 min
Hybridisation Overnight Overnight Overnight
Washing 4 min 20 min 4 min 11 min Washing, haematoxylin counterstain (15 sec), 
dehydration and mounting, 12 min
Dehydration No 6 min 3 min No
Drying 30 min Fast Fast No
DAPI staining Yes Yes Yes No
Detection No No No 147 min
Total duration Overnight
+ 3 h 12 min
Overnight
+ 1 h 57 min
Overnight
+ 7 min
Overnight
+ 3 h 55 min
3 h 2 min
Price (€ per test) 131 85 75 56 4
CISH, chromogenic in situ hybridisation; DAPI, 4,6-diamidino-2-phenylindole.Breast Cancer Research    Vol 9 No 5    Cayre et al.
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nucleus, diagnosis must be confirmed by using either a dual-
probe FISH kit as used in this study, or an internal control such
as the chromosome 17 SPoT-Light probe for CISH.
With the manufacturer's recommended threshold of at least
four signals per nucleus, concordance between PathVysion
and INFORM was only 76%, with a sensitivity of 100% but a
specificity of 57% (13 false positives). Application of the
thresholds of more than five or at least six signals per nucleus
to the INFORM results increased concordance with PathVys-
ion to 91% and 98%, respectively. The small amount of dis-
cordance was due to CEP17 polysomy, except in one
unexplained case. As with CISH, we advise a control with a
dual-probe FISH assay for borderline INFORM cases (five to
ten signals per nucleus). Our results compare well with those
recently published on an evaluation of three scoring methods
for FISH: dual-probe HER2:CEP17 or single-probe HER2
assay with a threshold of more than four or more than six sig-
nals per nucleus [20]. This study also recommended a thresh-
old of more than six signals per nucleus for FISH or a dual
probe HER2:CEP17 FISH assay for optimal HER2 scoring.
This was based on high concordance rates with IHC or
mRNA/assay/nucleic acid sequence-based amplification and
are in agreement with the recent American Society of Clinical
Oncology/College of American Pathologists guidelines for
HER2 testing [21]. The theoretical advantage of dual-probe
FISH analysis is the ability to distinguish chromosomal aneu-
ploidy from amplification by using a differentially labelled refer-
ence probe (CEP17). Although a single probe-based assay,
the main benefit of INFORM over other assays is that it is an
automated system.
Conclusion
We can draw several conclusions from this study. First, we
can validate CISH as a promising alternative to FISH for deter-
mining gene amplification, because it is easy to interpret and
the equipment can be readily found in most pathology depart-
ments. The potential of CISH as a HER2 status assay for rou-
tine practice has been the subject of an international
multicentre ring study, to which we have contributed, to vali-
date CISH against the current 'gold standards' [22]. Second,
the automated mono-probe assay INFORM provides the
opportunity for a more rapid evaluation of samples compared
with CISH and the two dual-probe FISH assays evaluated in
this study, provided that an appropriate threshold is applied.
Despite the clear benefits attributed to these two approaches,
we would advise that borderline CISH or single-probe FISH
results are controlled for by using a dual-probe FISH assay.
Table 5
Key features of the protocols for comparison
Feature PathVysion PharmDx INFORM CISH
Reagents Preparation required Ready to use Ready to use Ready to use
Stability of reagents pH requires checking OK OK OK
DAPI Bright Low intensity Not provided -
Background Orange fluorescence Strong; green fluorescence Faint; green fluorescence -
Stability of signal Good Rapid quenching of FITC 
signal
Good Excellent
HER2 probe Spectrum Orange; clear 
signal but high background 
fluorescence
Texas red; strong clear 
signal
FITC; strong clear signal Chromogenic; peroxidase-
based immunodetection, 
clear signal
CEP17 probe FITC; very strong signal, with 
blurring of large signals
FITC; faint and transient - -
Tissue morphology Poor definition; control with 
H&E to view areas of interest
Very poor definition; control 
with H&E to view areas of 
interest
Poor definition; control with 
H&E to view areas of interest
Good definition, allowing 
simultaneous analysis of 
amplification and 
histopathology
Microscope Fluorescent Fluorescent Fluorescent Normal light
Storage 1 year at -20°C 1 year at -20°C 1 year at -20°C Long period at ambient 
temperature
Threshold OK OK CISH threshold must be 
applied and borderline cases 
must be evaluated with a 
dual-probe method (5–10)
DAPI, 4,6-diamidino-2-phenylindole; HER2, human epidermal growth factor receptor 2; CEP17, chromosome enumeration probe 17; FITC, 
fluorescein isothiocyanate; H&E, haematoxylin and eosin staining; CISH, chromogenic in situ hybridisation.Available online http://breast-cancer-research.com/content/9/5/R64
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The ideal situation for pathologists in the future would be for
FDA approval of CISH in routine diagnosis and for automation
of the assay. The algorithm currently employed would then
change to that presented in Figure 1.
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